Update on HAART in HIV.

Area of Science:

• Infectious Diseases
• Virology
• Pharmacology

Background:

• Highly active antiretroviral combination therapy (HAART) has significantly reduced AIDS mortality since 1996.
• HIV infection has transitioned from a sub-acute lethal disease to a chronic ambulatory condition due to HAART.
• HAART typically involves a dual nucleoside reverse transcriptase inhibitor (NRTI) backbone combined with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r).

Purpose of the Study:

• To review the evolution and current status of antiretroviral therapy for HIV infection.
• To highlight advancements in first-line and salvage therapies.
• To discuss challenges and future directions in HIV drug discovery.

Main Methods:

• Review of current antiretroviral drug classes and combination strategies.
• Analysis of treatment efficacy and toxicity profiles.
• Examination of drug resistance patterns and salvage therapy options.

Main Results:

• Triple NRTI regimens show lower potency compared to other HAART combinations.
• First-line therapy is shifting towards more convenient and less toxic options, including co-formulated NRTIs and newer protease inhibitors like atazanavir.
• Novel drugs, including new protease inhibitors (tipranavir, TMC 114) and fusion inhibitors (T20), are available for salvage therapy against multi-drug resistant HIV.
• Despite progress, significant challenges remain, including patient mortality from multi-resistant viruses and increasing primary HIV resistance.

Conclusions:

• Antiretroviral therapy has dramatically improved HIV management, converting it into a chronic illness.
• Ongoing research and development are crucial for addressing drug resistance and improving treatment outcomes for all HIV patients.
• The development of convenient, less toxic, and potent antiretroviral regimens remains a priority.